Henrik Lundvall

Losing weight with hypothyroidism can be perceived as more difficult, even with healthy lifestyle habits. An underactive thyroid means lower levels of hormones that regulate metabolism, which can affect energy expenditure and stamina. However, the effect on body weight is usually moderate and varies between individuals. When hypothyroidism is treated and hormone levels normalize, the conditions for weight loss improve.

Understanding why the body does not always respond as expected to diet and physical activity is an important starting point for the right treatment. Lipedema and overweight can in some cases resemble each other, but are two different conditions with distinct underlying mechanisms. They can also occur simultaneously, which can further complicate the clinical picture.

The demand for medical treatment of obesity and overweight has increased significantly in recent times, which in turn has contributed to the emergence of a market where medicines are sometimes distributed outside established and regulated healthcare systems. Using these medications without a doctor's prescription, and without structured and continuous follow-up, entails significant medical risks.

Managing overweight is rarely a matter of willpower. The body's complex biological systems interact to regulate appetite, energy expenditure, and fat storage – often in a way that counteracts weight loss. Medical weight loss aims to influence these processes and create better conditions for sustainable results over time. Here, we go through how the medications work and who the treatment is suitable for.

Interest in new drug treatments for obesity has increased markedly in recent years. MariTide is a treatment under clinical development that could potentially contribute to an increased understanding of the body's weight regulation and broaden treatment options for obesity.

Body Mass Index (BMI) is one of the most widely used screening tools in healthcare for estimating the relationship between body weight and height. The measurement provides a general, statistical starting point for assessing the risk of various health conditions. At the same time, it is important to emphasize that BMI has limitations and cannot alone provide a complete picture of an individual's health status on its own.

CagriSema is a drug treatment under development for obesity. It combines two active substances, semaglutide and cagrilintide. By integrating two hormonal mechanisms of action, the treatment aims to influence both appetite regulation and glucose metabolism more comprehensively than treatment with a single substance.

KwikPen is a pre-filled multi-dose pen from the pharmaceutical company Eli Lilly, used to administer the medication Mounjaro. This type of pen is designed to facilitate regular dosing during medical weight loss and the treatment of type 2 diabetes. Here we go through how to handle the pen safely – from preparation to correct storage – to ensure your treatment works optimally.

New data proves sustainable weight loss delivers significant savings for patients.

‍
A pan-European survey of 1,350+ Yazen patients reveals a "health dividend" where effective obesity treatment offsets its own cost. By addressing biological cravings, patients save an average of €109 on food and €50 on healthcare monthly. Findings show a natural shift away from snacks and takeaways toward nutrient-dense, mindful consumption.